Compare
Anaptysbio, Inc vs Akebia Therapeutics, Inc. vs Puma Biotechnology, Inc. vs Keros Therapeutics, Inc.
| Latest fiscal year | Anaptysbio, Inc ANAB | Akebia Therapeutics, Inc. AKBA | Puma Biotechnology, Inc. PBYI | Keros Therapeutics, Inc. KROS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $234.60M | $236.20M | $228.37M | $244.06M |
| Revenue growth (YoY) | +157.0% | +47.5% | -0.9% | n/m |
| Gross margin | n/a | 83.3% (computed) | 74.5% (computed) | n/a |
| Operating margin | 20.4% | 9.9% | 16.3% | 27.7% |
| Net margin | -5.6% | -2.3% | 13.6% | 35.7% |
| Net income | -$13.23M | -$5.34M | $31.11M | $87.01M |
| EPS (Diluted) | -$0.46 | -$0.02 | $0.61 | $2.30 |
| Operating cash flow | $19.70M | $67.99M | $41.80M | $107.50M |
| Free cash flow | $19.61M | $67.70M | $41.73M | $105.95M |
| Cash & equivalents | $238.20M | $184.84M | $29.64M | $287.42M |
| Total assets | $364.39M | $376.56M | $216.30M | $338.02M |
| Total liabilities | n/a | $343.95M | $85.96M | $34.89M |
| Shareholders' equity | $37.21M | $32.61M | $130.34M | $303.13M |
| Return on year-end equity | -35.6% | -16.4% | 23.9% | 28.7% |
| Shares outstanding | 28.02M | 265.42M | 50.41M | 19.54M |
Revenue, most recent five fiscal years
| Fiscal year | Anaptysbio, Inc | Akebia Therapeutics, Inc. | Puma Biotechnology, Inc. | Keros Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $234.60M Ended 2025-12-31 | $236.20M Ended 2025-12-31 | $228.37M Ended 2025-12-31 | $244.06M Ended 2025-12-31 |
| 1 year earlier | $91.28M Ended 2024-12-31 | $160.18M Ended 2024-12-31 | $230.47M Ended 2024-12-31 | $3.55M Ended 2024-12-31 |
| 2 years earlier | $17.16M Ended 2023-12-31 | $194.62M Ended 2023-12-31 | $235.64M Ended 2023-12-31 | $151.0K Ended 2023-12-31 |
| 3 years earlier | $10.29M Ended 2022-12-31 | $292.48M Ended 2022-12-31 | $228.03M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | $63.17M Ended 2021-12-31 | $211.65M Ended 2021-12-31 | $253.16M Ended 2021-12-31 | $20.10M Ended 2021-12-31 |